An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma

Naruhiko Ikoma; Kanwal Raghav; George Chang

doi:10.1016/j.soc.2017.05.007

An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma

Naruhiko Ikoma, Kanwal Raghav, George Chang

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

There have been remarkable advances in the treatment of metastatic colorectal cancer over the past 20 years, chiefly achieved by development of new active drugs and establishment of effective systemic therapy regimens. Multidisciplinary care of resectable liver disease with use of perioperative systemic therapy and superior liver resection has resulted in prolonged survival of select patients. Median overall survival has significantly improved with the modern multiagent regimens. This article reviews recent high-quality randomized clinical trials that were conducted to address optimal treatment of advanced and metastatic colorectal carcinoma, mainly focused on initially inoperable metastatic disease.

Original language	English (US)
Pages (from-to)	667-687
Number of pages	21
Journal	Surgical oncology clinics of North America
Volume	26
Issue number	4
DOIs	https://doi.org/10.1016/j.soc.2017.05.007
State	Published - Oct 2017

Keywords

Chemotherapy
Metastatic colorectal cancer
Monoclonal antibody
Randomized controlled trial

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.soc.2017.05.007

Cite this

@article{8df57c7969474a0392117e4ab66fc5e8,

title = "An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma",

abstract = "There have been remarkable advances in the treatment of metastatic colorectal cancer over the past 20 years, chiefly achieved by development of new active drugs and establishment of effective systemic therapy regimens. Multidisciplinary care of resectable liver disease with use of perioperative systemic therapy and superior liver resection has resulted in prolonged survival of select patients. Median overall survival has significantly improved with the modern multiagent regimens. This article reviews recent high-quality randomized clinical trials that were conducted to address optimal treatment of advanced and metastatic colorectal carcinoma, mainly focused on initially inoperable metastatic disease.",

keywords = "Chemotherapy, Metastatic colorectal cancer, Monoclonal antibody, Randomized controlled trial",

author = "Naruhiko Ikoma and Kanwal Raghav and George Chang",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = oct,

doi = "10.1016/j.soc.2017.05.007",

language = "English (US)",

volume = "26",

pages = "667--687",

journal = "Surgical oncology clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma

AU - Ikoma, Naruhiko

AU - Raghav, Kanwal

AU - Chang, George

PY - 2017/10

Y1 - 2017/10

N2 - There have been remarkable advances in the treatment of metastatic colorectal cancer over the past 20 years, chiefly achieved by development of new active drugs and establishment of effective systemic therapy regimens. Multidisciplinary care of resectable liver disease with use of perioperative systemic therapy and superior liver resection has resulted in prolonged survival of select patients. Median overall survival has significantly improved with the modern multiagent regimens. This article reviews recent high-quality randomized clinical trials that were conducted to address optimal treatment of advanced and metastatic colorectal carcinoma, mainly focused on initially inoperable metastatic disease.

AB - There have been remarkable advances in the treatment of metastatic colorectal cancer over the past 20 years, chiefly achieved by development of new active drugs and establishment of effective systemic therapy regimens. Multidisciplinary care of resectable liver disease with use of perioperative systemic therapy and superior liver resection has resulted in prolonged survival of select patients. Median overall survival has significantly improved with the modern multiagent regimens. This article reviews recent high-quality randomized clinical trials that were conducted to address optimal treatment of advanced and metastatic colorectal carcinoma, mainly focused on initially inoperable metastatic disease.

KW - Chemotherapy

KW - Metastatic colorectal cancer

KW - Monoclonal antibody

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=85026741698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026741698&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2017.05.007

DO - 10.1016/j.soc.2017.05.007

M3 - Review article

C2 - 28923224

AN - SCOPUS:85026741698

SN - 1055-3207

VL - 26

SP - 667

EP - 687

JO - Surgical oncology clinics of North America

JF - Surgical oncology clinics of North America

IS - 4

ER -

An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this